Haldol Decanoas (Haloperidol Decanoate)

Haloperidol decanoate, the active component of Haldol Decanoas, is used as a long‑acting injectable antipsychotic for several psychiatric indications.

• Schizophrenia: maintenance treatment to reduce relapse risk in patients stabilized on oral antipsychotics.
• Acute psychotic episodes: short‑term control when oral therapy is not feasible or adherence is uncertain.
• Manic episodes of bipolar disorder: adjunctive therapy for rapid symptom control in acute phases.
• Tourette syndrome: reduction of motor and vocal tics as part of a comprehensive management plan.
• Long‑term maintenance: scheduled depot injections to ensure consistent drug levels and improve adherence.

The safety profile of haloperidol decanoate includes a range of adverse effects that vary in frequency and severity, and patients should be monitored regularly for both common and serious reactions.

Common

• Drowsiness or sedation, often noticeable within the first few days after injection.
• Extrapyramidal symptoms such as tremor, muscle rigidity, or akathisia that may affect mobility.
• Dry mouth, constipation, or increased salivation, reflecting anticholinergic activity.
• Weight gain and metabolic changes, including increased appetite and altered lipid profiles.

Serious

• Tardive dyskinesia, a potentially irreversible condition marked by involuntary, repetitive facial or limb movements.
• Neuroleptic malignant syndrome, a rare but life‑threatening reaction presenting with high fever, severe muscle rigidity, autonomic instability, and altered mental status.
• Severe hypotension or cardiac arrhythmias, which may require urgent medical evaluation and intervention.

When prescribing or receiving Haldol Decanoas, several precautions should be considered to minimize risks and ensure appropriate use.

• Assess pregnancy status and discuss potential risks, as safety data in pregnancy are limited.
• Use caution in elderly patients, especially those with dementia-related psychosis, due to increased sensitivity to side effects.
• Evaluate hepatic and renal function before initiating therapy, adjusting the treatment plan if impairment is present.
• Monitor regularly for extrapyramidal symptoms, tardive dyskinesia, and signs of neuroleptic malignant syndrome.
• Screen for cardiovascular disease, as the drug may cause orthostatic hypotension or QT prolongation.
• Avoid abrupt discontinuation; tapering is recommended to reduce the risk of withdrawal phenomena.

Haloperidol decanoate can interact with several medications, affecting its efficacy or increasing the risk of adverse events.

Avoid

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) that may raise plasma concentrations and heighten side‑effect risk.
• Concurrent use with other antipsychotics, which can amplify extrapyramidal symptoms and cardiac effects.
• CNS depressants such as benzodiazepines or opioids, increasing sedation and respiratory depression.

Use with caution

• CYP3A4 inducers (e.g., carbamazepine, rifampin) that may lower drug levels and reduce therapeutic effect.
• QT‑prolonging agents (e.g., certain antiarrhythmics, macrolide antibiotics) that can compound cardiac conduction risks.
• Antihypertensive agents (e.g., alpha‑blockers) may enhance orthostatic hypotension.